Contribute Try STAT+ Today

A biotech startup that aims to revive a failed drug candidate with a precision approach to treating Alzheimer’s just brought a big name on board: Nobel laureate Dr. Stanley Prusiner, a pioneer in researching prion diseases.

Prusiner, a biologist based at the University of California, San Francisco, will join Alzheon, Inc. as chair of the scientific advisory board, said Alzheon founder and CEO Dr. Martin Tolar.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • My mother has Alzheimer disease, since 2008. She has 72 years old, she does not speak any more. We have visit all fisicians in México but they do not give su any hope. What can l do for my mother? What kind of study she can take?

Comments are closed.